Q-omics provides the consensus-scored ZP4 profile across patient tissues and cancer cell-line models. ZP4 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZP4 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, ZP4 RNA expression shows 6,584 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, HNSC, and STAD as cancer lineages where ZP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZP4 survival associations across molecular data types. ZP4 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZP4 RNA expression–survival associations across cancer types. High ZP4 expression shows unfavorable associations in LIHC, KIRC and CHOL, but favorable associations in UVM, CESC and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZP4 RNA expression.
This table summarizes ZP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZP4 shows higher tumor expression in HNSC, BRCA, LUSC, LUAD and KICH. The HNSC box plot shows higher ZP4 RNA expression in tumor versus normal tissue (log2 FC = +0.080, t-test p < 0.001).
This table shows molecular features associated with ZP4 in patient tissues and cancer cell lines. In patient samples, ZP4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ZP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
